Description
General description
Anti-c-myc is a monoclonal antibody to c-myc peptide (clone 9E10). Anti-c-myc recognizes the 9E10 epitope sequence (EQKLISEEDL), derived from the human c-myc protein. The monoclonal antibody against the c-myc epitope is well characterized and does not cross-react with other cellular proteins. The antibody recognizes its antigenic determinant even when the c-myc peptide epitope is introduced into unrelated recombinant proteins by a technique known as epitope tagging.
The cellular myelocytomatosis (c-myc) is the cellular homologue of the v-myc gene originally isolated from an avian myelocytomatosis virus. The gene encoding it is mapped to human chromosome 8q24. It c-myc is a member of MYC gene family. c-Myc gene codes for basic helix-loop-helix/leucine zipper (bHLH/LZ) transcription factor that regulates the G1-S cell cycle transition.
Contents:
11 667 149 001: lyophilizate, stabilized
11 667 203 001: frozen solution, (5 mg/ml)
Immunogen
Amino acid sequence EQKLISEEDL was derived from the human c-myc protein.
Application
Use Anti-c-myc for the detection of native human c-myc protein and recombinant epitope-tagged proteins that contain the c-myc epitope using:
Dot blots
Immunocytochemistry
Immunoprecipitation
Western blots
Immunohistochemistry.
Biochem/physiol Actions
The cellular myelocytomatosis (c-myc) oncogene has a crucial role in cellular proliferation, differentiation, apoptosis and acts as transcriptional regulator of gene expression. c-myc expression is essential and sufficient to assist most of the cells to enter DNA synthetic (S) phase of the cell cycle. The encoded protein plays a crucial role in vasculogenesis and angiogenesis during cancer development and progression. c-myc interacts with its binding partner Max and activates the transcription of growth promoting genes such as cyclin D2 and ornithine decarboxylase. It also represses the transcription of multiple genes, especially p21 and p27, by binding to the transcription initiator element (Inr) in a complex with Max and either Sp1 (specificity protein 1) or Miz1 (Myc-interacting zinc finger protein 1). Overexpression of MYC in DLBCL (diffuse large B-cell lymphoma) results in poor outcome and invasive treatment when medicated with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP).
Anti-c-myc recognizes the amino acid sequence EQKLISEEDL, which was derived from the human c-myc protein. The antibody recognizes its antigenic determinant even when the c-myc peptide epitope is introduced into unrelated recombinant proteins either N-terminal, C-terminal or internal. The monoclonal antibody against the c-myc epitope is well characterized and does not crossreact with other cellular proteins.
Preparation Note
Working concentration: Working concentration of conjugate depends on application and substrate.
The following concentrations should be taken as a guideline:
Western blot: 1 to 10 μg/ml
Working solution: Tris-buffered saline containing 0.1% Tween 20.
Add 500 μl PBS to a final concentration of 400 μg/ml.
Analysis Note
Anti-c-myc antibody is tested for functionality and purity relative to a reference standard to confirm the quality of each new reagent lot.
The monoclonal antibody against the c-myc epitope is well characterized and does not crossreact with other cellular proteins. No cross reaction with murine c-myc.
Other Notes
For life science research only. Not for use in diagnostic procedures.
